Log in

NYSE:BHVNBiohaven Pharmaceutical Stock Price, Forecast & News

$62.47
+4.67 (+8.08 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$57.11
Now: $62.47
$62.59
50-Day Range
$33.64
MA: $45.90
$60.11
52-Week Range
$26.56
Now: $62.47
$67.86
Volume770,423 shs
Average Volume729,245 shs
Market Capitalization$3.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut.
Read More
Biohaven Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:BHVN
CUSIPN/A
Phone203-404-0410

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.08 per share

Profitability

Net Income$-528,800,000.00

Miscellaneous

Employees63
Market Cap$3.66 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

How has Biohaven Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BHVN stock has increased by 58.3% and is now trading at $62.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biohaven Pharmaceutical?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biohaven Pharmaceutical.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Biohaven Pharmaceutical.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($2.39) earnings per share for the quarter, topping the Zacks' consensus estimate of ($2.46) by $0.07. The firm had revenue of $1.10 million for the quarter, compared to analysts' expectations of $0.21 million. During the same quarter in the prior year, the business earned ($1.41) EPS. View Biohaven Pharmaceutical's earnings history.

What price target have analysts set for BHVN?

12 brokerages have issued 1-year target prices for Biohaven Pharmaceutical's stock. Their forecasts range from $41.00 to $100.00. On average, they expect Biohaven Pharmaceutical's share price to reach $65.82 in the next year. This suggests a possible upside of 5.4% from the stock's current price. View analysts' price targets for Biohaven Pharmaceutical.

Has Biohaven Pharmaceutical been receiving favorable news coverage?

Media headlines about BHVN stock have trended somewhat negative recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutBiohaven Pharmaceutical.

Are investors shorting Biohaven Pharmaceutical?

Biohaven Pharmaceutical saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 10,270,000 shares, an increase of 8.8% from the March 31st total of 9,440,000 shares. Based on an average daily volume of 1,110,000 shares, the days-to-cover ratio is presently 9.3 days. Approximately 20.5% of the shares of the stock are sold short. View Biohaven Pharmaceutical's Current Options Chain.

Who are some of Biohaven Pharmaceutical's key competitors?

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Advanced Micro Devices (AMD), Micron Technology (MU), Crispr Therapeutics (CRSP), Biopharmx (BPMX), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Netflix (NFLX).

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:
  • Dr. Vladimir Coric, CEO & Director (Age 48)
  • Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)
  • Dr. Charles Conway, Chief Scientific Officer (Age 57)
  • Mr. Clifford Bechtold, Chief Operating Officer
  • Mr. Matthew DeLawder, Director of Accounting

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital International Investors (10.26%), BlackRock Inc. (5.61%), Wellington Management Group LLP (5.33%), Capital World Investors (3.75%), State Street Corp (3.38%) and Eventide Asset Management LLC (3.05%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View institutional ownership trends for Biohaven Pharmaceutical.

Which major investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Nuveen Asset Management LLC, Pictet Asset Management Ltd., Two Sigma Investments LP, Two Sigma Advisers LP, Spark Investment Management LLC, Alliancebernstein L.P., and Rafferty Asset Management LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Elyse Stock, Eric Aguiar, John W Childs, Kimberly Gentile, and Robert Berman. View insider buying and selling activity for Biohaven Pharmaceutical.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Capital World Investors, BlackRock Inc., Wells Fargo & Company MN, NWI Management LP, Foresite Capital Management IV LLC, and Eventide Asset Management LLC. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric. View insider buying and selling activity for Biohaven Pharmaceutical.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $62.47.

How big of a company is Biohaven Pharmaceutical?

Biohaven Pharmaceutical has a market capitalization of $3.66 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.